Compare CNMD & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNMD | TNDM |
|---|---|---|
| Founded | 1970 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1987 | 2013 |
| Metric | CNMD | TNDM |
|---|---|---|
| Price | $43.35 | $22.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 16 |
| Target Price | ★ $53.67 | $24.00 |
| AVG Volume (30 Days) | 588.6K | ★ 1.4M |
| Earning Date | 01-28-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $1,347,470,000.00 | $1,007,001,000.00 |
| Revenue This Year | $6.81 | $8.59 |
| Revenue Next Year | $0.64 | $10.19 |
| P/E Ratio | $21.21 | ★ N/A |
| Revenue Growth | 4.61 | ★ 17.87 |
| 52 Week Low | $38.32 | $9.98 |
| 52 Week High | $74.70 | $38.28 |
| Indicator | CNMD | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 59.21 |
| Support Level | $40.15 | $21.35 |
| Resistance Level | $41.62 | $23.95 |
| Average True Range (ATR) | 1.32 | 0.87 |
| MACD | 0.50 | -0.10 |
| Stochastic Oscillator | 82.48 | 55.02 |
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.